Skip to main content
PMC home page
Environmental Health Perspectives logoLink to Environmental Health Perspectives
. 1976 Jun;15:3–12. doi: 10.1289/ehp.76153

Various forms of chemically induced liver injury and their detection by diagnostic procedures.

H J Zimmerman
PMCID: PMC1475160  PMID: 1001294

Abstract

A large number of chemical agents, administered for therapeutic or diagnostic purposes, can produce various types of hepatic injury by several mechanisms. Some agents are intrinsically hepatotoxic, and others produce hepatic injury only in the rare, uniquely susceptible individual. Idiosyncrasy of the host is the mechanism for most types of drug-induced hepatic injury. It may reflect allergy to the drug or a metabolic aberation of the host permitting the accumulation of hepatotoxic metabolites. The syndromes of hepatic disease produced by drugs have been classified hepatocellular, hepatocanalicular, mixed and canalicular. Measurement of serum enzyme activities has provided a powerful tool for studies of hepatotoxicity. Their measurement requires awareness of relative specificity, knowledge of the mechanisms involved, and knowledge of the relationship between known hepatotoxic states and elevated enzyme activities.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Acocella G., Nicolis F. B., Tenconi L. T. The effect of an intravenous infusion of rifamycin SV on the excretion of bilirubin, bromsulphalein, and indocyanine green in man. Gastroenterology. 1965 Nov;49(5):521–525. [PubMed] [Google Scholar]
  2. BOAKE W. C., SCHADE S. G., MORRISSEY J. F., SCHAFFNER F. INTRAHEPATIC CHOLESTATIC JAUNDICE OF PREGNANCY FOLLOWED BY ENOVID-INDUCED CHOLESTATIC JAUNDICE: REPORT OF A CASE. Ann Intern Med. 1965 Aug;63:302–308. doi: 10.7326/0003-4819-63-2-302. [DOI] [PubMed] [Google Scholar]
  3. Dahl M. G., Gregory M. M., Scheuer P. J. Liver damage due to methotrexate in patients with psoriasis. Br Med J. 1971 Mar 20;1(5750):625–630. doi: 10.1136/bmj.1.5750.625. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Dujovne C. A., Levy R., Zimmerman H. J. Hepatotoxicity of phenothiazines in vitro as measured by loss of aminotransferases to surrounding media. Proc Soc Exp Biol Med. 1968 Jun;128(2):561–563. doi: 10.3181/00379727-128-33066. [DOI] [PubMed] [Google Scholar]
  5. Dujovne C. A., Shoeman D., Bianchine J., Lasagna L. Experimental bases for the different hepatotoxicity of erythromycin preparations in man. J Lab Clin Med. 1972 May;79(5):832–844. [PubMed] [Google Scholar]
  6. Gallagher T. F., Jr, Mueller M. N., Kappas A. Estrogen pharmacology. IV. Studies of the structural basis for estrogen-induced impairment of liver function. Medicine (Baltimore) 1966 Nov;45(6):471–479. [PubMed] [Google Scholar]
  7. Kendler J., Anuras S., Laborda O., Zimmerman H. J. Perfusion of the isolated rat liver with erythromycin estolate and other derivatives. Proc Soc Exp Biol Med. 1972 Apr;139(4):1272–1275. doi: 10.3181/00379727-139-36345. [DOI] [PubMed] [Google Scholar]
  8. Kendler J., Bowry S., Seeff L. B., Zimmerman H. J. Effect of chlorpromazine on the function of the perfused isolated liver. Biochem Pharmacol. 1971 Sep;20(9):2439–2445. doi: 10.1016/0006-2952(71)90244-9. [DOI] [PubMed] [Google Scholar]
  9. Levine B. B. Immunochemical mechanisms of drug allergy. Annu Rev Med. 1966;17:23–38. doi: 10.1146/annurev.me.17.020166.000323. [DOI] [PubMed] [Google Scholar]
  10. Opolon P., Cartron J., Chicot D., Caroli J. Application du test de transformation lymphoblastique (TTL) au diagnostic de certaines hépatites médicamenteuses. Presse Med. 1969 Dec 20;77(54):2041–2044. [PubMed] [Google Scholar]
  11. Paronetto F., Popper H. Lymphocyte stimulation induced by halothane in patients with hepatitis following exposure to halothane. N Engl J Med. 1970 Aug 6;283(6):277–280. doi: 10.1056/NEJM197008062830602. [DOI] [PubMed] [Google Scholar]
  12. Peters R. L., Edmondson H. A., Reynolds T. B., Meister J. C., Curpey T. J. Hepatic necrosis associated with halothane anesthesia. Am J Med. 1969 Nov;47(5):748–764. doi: 10.1016/0002-9343(69)90168-5. [DOI] [PubMed] [Google Scholar]
  13. Reynolds T. B., Peters R. L., Yamada S. Chronic active and lupoid hepatitis caused by a laxative, oxyphenisatin. N Engl J Med. 1971 Oct 7;285(15):813–820. doi: 10.1056/NEJM197110072851501. [DOI] [PubMed] [Google Scholar]
  14. Schaffner F., Raisfeld I. H. Drugs and the liver: a review of metabolism and adverse reactions. Adv Intern Med. 1969;15:221–251. [PubMed] [Google Scholar]
  15. Slater T. F. Necrogenic action of carbon tetrachloride in the rat: a speculative mechanism based on activation. Nature. 1966 Jan 1;209(5018):36–40. doi: 10.1038/209036a0. [DOI] [PubMed] [Google Scholar]
  16. Trey C., Davidson C. S. The management of fulminant hepatic failure. Prog Liver Dis. 1970;3:282–298. [PubMed] [Google Scholar]
  17. Zimmerman H. J., Kendler J. Relationship between structure of phenothiazines and in vitro cytotoxicity. Proc Soc Exp Biol Med. 1970 Nov;135(2):201–205. doi: 10.3181/00379727-135-35019. [DOI] [PubMed] [Google Scholar]
  18. Zimmerman H. J. The spectrum of hepatotoxicity. Perspect Biol Med. 1968 Autumn;12(1):135–161. doi: 10.1353/pbm.1968.0004. [DOI] [PubMed] [Google Scholar]

Articles from Environmental Health Perspectives are provided here courtesy of National Institute of Environmental Health Sciences

RESOURCES